TYME - Tyme Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6400
-0.0900 (-5.20%)
As of 3:15PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.7300
Open1.7100
Bid1.6300 x 1100
Ask1.6400 x 800
Day's Range1.5800 - 1.7215
52 Week Range0.9200 - 4.6420
Volume214,826
Avg. Volume908,734
Market Cap183.6M
Beta (3Y Monthly)0.57
PE Ratio (TTM)N/A
EPS (TTM)-0.2800
Earnings DateAug 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Trade prices are not sourced from all markets
  • GlobeNewswire

    Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019. The Company will present its corporate overview for 2019 with a special focus on growth opportunities driven by advancements in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate, and sarcoma cancers. A live webcast of the presentation will be accessible on the events page under the Investor Relations section of Tyme Technologies’ website at www.tymeinc.com.

  • Will Tyme Technologies Continue to Surge Higher?
    Zacks

    Will Tyme Technologies Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Tyme Technologies.

  • GlobeNewswire

    TYME Presents Positive Circulating Tumor Cell Data from TYME-88-Panc Study in Patients with Advanced Pancreatic Cancer at AACR PANC 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), reported encouraging data on circulating tumor cells (CTCs) and a correlation with decrease in risk of death using TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer. The data were presented at the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, taking place September 6-9, 2019, at the Westin Copley Place in Boston, Massachusetts.

  • GlobeNewswire

    Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright in New York City on Monday, September 9, 2019. The Company will present its corporate overview for 2019 with special focus on growth opportunities driven by advances in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers.

  • GlobeNewswire

    TYME Announces Abstracts Selected for Presentation at the European Society of Medical Oncology Congress 2019

    SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancersNew oral approach aimed at.

  • GlobeNewswire

    Tyme Technologies to Present at BTIG Biotechnology Conference on August 12th, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the BTIG Biotechnology Conference in New York on August 12th, 2019. In one-on-one sessions, the Company will present its corporate overview for 2019 with special focus on growth opportunities driven by advances in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers.

  • GlobeNewswire

    TYME Provides Business Update and Reports First Quarter Fiscal 2020 Financial and Operating Results

    TYME Presented Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic CancerNYU.

  • GlobeNewswire

    TYME Announces Abstracts Selected for Presentation at the AACR Special Conference on Pancreatic Cancer

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that two abstracts highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer have been selected for poster presentation at the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, taking place September 6-9, 2019, at the Westin Copley Place in Boston, Massachusetts. Additional information on the meeting can be found on the AACR Special Conference on Pancreatic Cancer website: https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=180.

  • GlobeNewswire

    Tyme Technologies to Present at the 39th Annual Canaccord Genuity Growth Conference on August 7th, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 39th Annual Canaccord Genuity Growth Conference in Boston on August 7th, 2019. The Company will present its corporate overview for 2019 with special focus on growth opportunities driven by advances in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers.

  • GlobeNewswire

    TYME Technologies Announces New Collaboration with NYU Langone to Advance TYME’s Cancer Metabolism-Based Therapy, SM-88

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company, announced a new research collaboration with NYU Langone Health to advance the development of innovative treatments for patients with metastatic cancers, including pancreatic cancer. The collaboration will leverage NYU Langone’s state-of-the-art technologies to help inform the development of clinical therapies, focusing on identifying potential future biomarkers or combination approaches to treat cancer. “We are excited to collaborate on this new effort to help uncover key findings about how specific biomarkers may help slow the development of certain cancer types,” said Diane Simeone, MD, Director of the Pancreatic Cancer Center at NYU Langone Health’s Perlmutter Cancer Center and Lead Principle Investigator for the Pancreatic Cancer Network’s Precision PromiseSM trials.

  • GlobeNewswire

    REMINDER - TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

    TYME management will be hosting a conference call on July 9th at 8:30AM EDT to discuss the SM-88 data presented at the ESMO GI Congress. NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its multicenter open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging results and a well-tolerated safety profile.

  • Tyme Technologies News: Why TYME Stock Is Rocketing
    InvestorPlace

    Tyme Technologies News: Why TYME Stock Is Rocketing

    Tyme Technologies (NASDAQ:TYME) stock is skyrocketing on Friday following the company's announcement regarding the latest data from one of its cancer treatments.Source: Shutterstock The U.S. biotechnology company revealed that it had amassed positive updated data regarding its phase 2 study of SM-88, which is a treatment designed to help out patients with pancreatic cancer. This led to trading volume increasing to more than 4.1 million shares, which is more than six times the full-day average.Tyme Technologies said before the open that data from the study of SM-88 as an oral monotherapy revealed that the median overall survival of patients was 6.4 months, which compares favorably next to historical trials that showed survival of 2.0 to 2.5 months. "We believe that these outcomes further justify advancing the development of SM-88," said Chief Medical Officer Giuseppe Del Priore.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are increasingly encouraged that SM-88 has the potential to be a new treatment approach for late-stage pancreatic patients," he added.TYME stock is soaring about 22.5% on Friday afternoon following the news, which brought the price of the stock up to $1.50 per share. The stock had closed at around $1.22 per share by day's end on Wednesday, which is the price it opened at today-the stock market was not open yesterday in observation of Independence Day.The stock is still down more than 50% year-to-date, although the boost helped it move in the right direction. More From InvestorPlace * The Top 8 Tech Stocks of 2019 (So Far) * The 7 Top Small-Cap Stocks Of 2019 * 7 F-Rated Stocks to Sell for Summer * 7 Retail Stocks to Buy That Are Down in 2019 The post Tyme Technologies News: Why TYME Stock Is Rocketing appeared first on InvestorPlace.

  • MarketWatch

    Tyme Technologies stock soars on heavy volume after upbeat update to cancer treatment study

    Shares of Tyme Technologies Inc. shot up 31% in active morning trading Friday, after the biotechnology company provided upbeat updated data from its phase 2 study of SM-88 for the treatment of pancreatic cancer. Trading volume swelled to 4.1 million shares, or already more than six-times the full-day average. The company said before the open that data from the study of SM-88 as an oral monotherapy showed that median overall survival of patients was 6.4 months, which compares favorably to historical trials which showed survival of 2.0 to 2.5 months. "We believe that these outcomes further justify advancing the development of SM-88," said Chief Medical Officer Giuseppe Del Priore. "We are increasingly encouraged that SM-88 has the potential to be a new treatment approach for late-stage pancreatic patients." Despite Friday's rally, the stock was still down 57% year to date, while the iShares Nasdaq Biotechnology ETF has gained 14% and the S&P 500 has advanced 19%.

  • GlobeNewswire

    TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

    Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its multicenter open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging results and a well-tolerated safety profile. The data from the TYME-88-Panc study were presented at the European Society of Medical Oncology 21st World Congress on Gastrointestinal Cancer (ESMO GI) on July 4, 2019 in Barcelona, Spain.

  • Will Tyme Technologies, Inc.'s (NASDAQ:TYME) Earnings Grow Over The Next Few Years?
    Simply Wall St.

    Will Tyme Technologies, Inc.'s (NASDAQ:TYME) Earnings Grow Over The Next Few Years?

    In June 2019, Tyme Technologies, Inc. (NASDAQ:TYME) released its most recent earnings announcement, which revealed...

  • GuruFocus.com

    Weekly CFO Buys Highlight

    Recent buys from company CFOs

  • GlobeNewswire

    TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that an abstract highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer has been selected for poster presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer (ESMO GI) being held on July 3-6, 2019 in Barcelona, Spain. Additional information on the meeting can be found on the ESMO World Congress on Gastrointestinal Cancer website: https://www.worldgicancer.com.

  • GlobeNewswire

    TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results

    TYME-88-Panc Continues to Show Encouraging Survival Trend with Additional Data to Be Presented in Third Quarter 2019Single Agent SM-88 (racemetyrosine) Shown to Have Anti-Tumor.

  • The Tyme Technologies (NASDAQ:TYME) Share Price Is Down 83% So Some Shareholders Are Rather Upset
    Simply Wall St.

    The Tyme Technologies (NASDAQ:TYME) Share Price Is Down 83% So Some Shareholders Are Rather Upset

    It's not possible to invest over long periods without making some bad investments. But you want to avoid the really...

  • GlobeNewswire

    Tyme Technologies to Present at the Jefferies 2019 Global Healthcare Conference on June 7, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Jefferies Global Healthcare Conference in New York on June 7, 2019. The company will present their corporate overview for 2019 with special focus on advances in the science of cancer metabolism and clinical developments for their lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

  • GlobeNewswire

    Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the company will host a conference call and live webcast on Wednesday, May 29, 2019, at 8:30 A.M. ET to report its fourth quarter and fiscal year 2019 financial and operating results. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties.

  • GlobeNewswire

    TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced the initiation of the HopES trial conducted in partnership with The Joseph Ahmed Foundation to better understand and help manage high-risk sarcomas which are ultra-rare cancers with high unmet medical need. "There is an urgent need for more effective treatment options for patients with high-risk sarcomas, including Ewing’s sarcoma,” said Sant Chawla, M.D., Director of the Sarcoma Oncology Research Center, Santa Monica, CA and lead investigator for the HopES trial. "I was encouraged by the initial clinical trial data for SM-88 in metastatic sarcomas.  This study has the potential to provide a new treatment option for patients with Ewing’s sarcoma who do not reach complete remission with first line treatment and patients with other sarcomas after progression.

  • GlobeNewswire

    TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers

    Tyme Technologies, Inc.  (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that it has received notification that the United States Patent and Trademark Office (USPTO) intends to issue another patent related to TYME’s technology platform. U.S. Patent No.10,307,465 will be directed to methods for treating cancer using tyrosine hydroxylase inhibitors, such as TYME’s lead compound SM-88 (racemetyrosine), to make cancer cells more accessible to oxidative stress.

  • GlobeNewswire

    Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will participate at the Oppenheimer Oncology Insight Summit in New York on Thursday, May 16, 2019. In one-on-one settings, the company will present its corporate overview for 2019 with special focus on advances in the science of cancer metabolism and clinical developments in lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers. The presentation will be accessible on the events page under the Investor Relations section of Tyme Technologies’ website at www.tymeinc.com.

  • GlobeNewswire

    Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2019 at the BioNJ 9th Annual BioPartnering Conference on Wednesday, May 8, 2019. Co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, the conference brings together biopharmaceutical companies, investors, and academic collaborators across the Northeast to Mid-Atlantic states. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer metabolism-based therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.